HealthQuill Acquisition
Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.
Drugs Health Pharma

Novartis AG to acquire Exellergy for $2 billion, expand allergy portfolio

Novartis AG will buy a US-based private biotech company, Excellergy, Inc, for $2 billion to expand its allergy portfolio.

Read More
Merck & Co will buy Terns Pharmaceuticals, Inc., a clinical-stage oncology company, for $6.7 billion to pocket an investigational drug to treat a type of blood cancer, according to a statement.
Drugs Health Pharma

Merck to buy Terns for $6.7 billion as Keytruda drug patent loss looms

Merck & Co will buy Terns Pharmaceuticals, Inc., a clinical-stage oncology company, for $6.7 billion to pocket an investigational drug to treat a.

Read More
Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for $2 billion, according to a statement. 
Drugs Medical Pharma

Gilead Sciences to acquire US-based Ouro Medicines for up to $2 billion 

Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for.

Read More
Novartis AG has agreed to buy an investigational oral medicine of Pikavation Therapeutics, a subsidiary of privately-held Synnovation Therapeutics, to treat breast cancer, for a deal worth $3 billion.
Drugs Medical Pharma

Novartis AG to buy experimental oral drug of Pikavation for $3 billion

Novartis AG has agreed to buy an investigational oral medicine of Pikavation Therapeutics, a subsidiary of privately-held Synnovation Therapeutics, to treat breast cancer, for.

Read More
Hologic Inc., which specialises in women’s health diagnostics, is set to be acquired in a deal worth $18.3 billion backed by asset managers Blackstone and TGP.
Drugs Health Pharma

Asset managers Blackstone, TGP to acquire Hologic for $18.3 billion

Hologic Inc., which specialises in women’s health diagnostics, is set to be acquired in a deal worth $18.3 billion backed by asset managers.

Read More
Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease, the company announced.
Drugs Health Pharma

Novo to buy Akero for $5.2 billion, to pocket trial liver disease drug

Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease,.

Read More
Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its metabolic disease portfolio.
Drugs Health Pharma

Roche to buy 89bio Inc for $3.5 billion to expand metabolic disease portfolio

Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its.

Read More
Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion to gain access to a respiratory drug approved by the US regulator, according to a statement from Merck.
Drugs Health Pharma

Merck to acquire Verona Pharma for $10 billion to net respiratory drug 

HQ Team July 9, 2025: Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion and gain access to a.

Read More
Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a cell, for $425 million, according to a company statement.
Drugs Health Pharma

Illumina to acquire proteomics company SomaLogic in $425 million all cash deal

HQ Team June 23, 2025: Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a.

Read More
Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, to gain access to a medicine to treat postpartum depression.
Drugs Health Pharma

Supernus Pharma to acquire Sage Therapeutics for $795 million all cash

HQ Team June 22, 2025: Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, as.

Read More